Anti-Obesity Activity of the Marine Carotenoid Fucoxanthin

被引:226
作者
Gammone, Maria Alessandra [1 ]
D'Orazio, Nicolantonio [1 ]
机构
[1] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Human & Clin Nutr Unit, I-66013 Chieti, Italy
来源
MARINE DRUGS | 2015年 / 13卷 / 04期
关键词
WHITE ADIPOSE-TISSUE; DIET-INDUCED OBESITY; NF-KAPPA-B; WEIGHT-GAIN; DOCOSAHEXAENOIC ACID; LIPID-METABOLISM; DOWN-REGULATION; GUT MICROBIOTA; BLOOD-GLUCOSE; HEPG2; CELLS;
D O I
10.3390/md13042196
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nowadays the global tendency towards physical activity reduction and an augmented dietary intake of fats, sugars and calories is leading to a growing propagation of overweight, obesity and lifestyle-related diseases, such diabetes, hypertension, dyslipidemia and metabolic syndrome. In particular, obesity, characterized as a state of low-level inflammation, is a powerful determinant both in the development of insulin resistance and in the progression to type 2 diabetes. A few molecular targets offer hope for anti-obesity therapeutics. One of the keys to success could be the induction of uncoupling protein 1 (UCP1) in abdominal white adipose tissue (WAT) and the regulation of cytokine secretions from both abdominal adipose cells and macrophage cells infiltrated into adipose tissue. Anti-obesity effects of fucoxanthin, a characteristic carotenoid, exactly belonging to xanthophylls, have been reported. Nutrigenomic studies reveal that fucoxanthin induces UCP1 in abdominal WAT mitochondria, leading to the oxidation of fatty acids and heat production in WAT. Fucoxanthin improves insulin resistance and decreases blood glucose levels through the regulation of cytokine secretions from WAT. The key structure of anti-obesity effect is suggested to be the carotenoid end of the polyene chromophore, which contains an allenic bond and two hydroxyl groups. Fucoxanthin, which can be isolated from edible brown seaweeds, recently displayed its many physiological functions and biological properties. We reviewed recent studies and this article aims to explain essential background of fucoxanthin, focusing on its promising potential anti-obesity effects. In this respect, fucoxanthin can be developed into promising marine drugs and nutritional products, in order to become a helpful functional food.
引用
收藏
页码:2196 / 2214
页数:19
相关论文
共 67 条
  • [1] The effects of Xanthigen™ in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat
    Abidov, M.
    Ramazanov, Z.
    Seifulla, R.
    Grachev, S.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (01) : 72 - 81
  • [2] Effect of Brown Seaweed Lipids on Fatty Acid Composition and Lipid Hydroperoxide Levels of Mouse Liver
    Airanthi, M. K. Widjaja-Adhi
    Sasaki, Naoya
    Iwasaki, Sayaka
    Baba, Nobuko
    Abe, Masayuki
    Hosokawa, Masashi
    Miyashita, Kazuo
    [J]. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2011, 59 (08) : 4156 - 4163
  • [3] Biotransformation of fucoxanthinol into amarouciaxanthin A in mice and HepG2 cells: Formation and cytotoxicity of fucoxanthin metabolites
    Asai, A
    Sugawara, T
    Ono, H
    Nagao, A
    [J]. DRUG METABOLISM AND DISPOSITION, 2004, 32 (02) : 205 - 211
  • [4] Low bioavailability of dietary epoxyxanthophylls in humans
    Asai, Akira
    Yonekura, Lina
    Nagao, Akihiko
    [J]. BRITISH JOURNAL OF NUTRITION, 2008, 100 (02) : 273 - 277
  • [5] Aster J., 2010, ROBBINS COTRAN PATHO, V33, P340
  • [6] Down-Regulation of Hepatic Stearoyl-CoA Desaturase-1 Expression by Fucoxanthin via Leptin Signaling in Diabetic/Obese KK-A y Mice
    Beppu, Fumiaki
    Hosokawa, Masashi
    Yim, Mi-Jin
    Shinoda, Taro
    Miyashita, Kazuo
    [J]. LIPIDS, 2013, 48 (05) : 449 - 455
  • [7] Effects of dietary fucoxanthin on cholesterol metabolism in diabetic/obese KK-Ay mice
    Beppu, Fumiaki
    Hosokawa, Masashi
    Niwano, Yoshimi
    Miyashita, Kazuo
    [J]. LIPIDS IN HEALTH AND DISEASE, 2012, 11
  • [8] Appetite control and energy balance: impact of exercise
    Blundell, J. E.
    Gibbons, C.
    Caudwell, P.
    Finlayson, G.
    Hopkins, M.
    [J]. OBESITY REVIEWS, 2015, 16 : 67 - 76
  • [9] Brondani LD, 2012, ARQ BRAS ENDOCRINOL, V56, P215, DOI 10.1590/S0004-27302012000400001
  • [10] Clement K, 1996, INT J OBESITY, V20, P1062